Actively Recruiting
Phase 2 Trial Evaluating Safety and Function of AMC6156 Tablets in Older Adults with Sarcopenia
Led by Animuscure Inc. · Updated on 2026-08-03
80
Participants Needed
4
Research Sites
15 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying AMC6156 to see if it can improve physical function and is safe for older adults with sarcopenia, a condition characterized by muscle loss and weakness. This phase 2 clinical trial involves adults aged 65 and older who have been diagnosed with sarcopenia based on specific muscle mass and strength criteria. Participants will be randomly assigned to one of four groups three different daily doses of AMC6156 tablets 0.1 mg, 0.3 mg, or 1.0 mg or a placebo, taken once a day for 12 weeks. This parallel study compares the effects of the different doses of AMC6156 against the placebo to evaluate safety and effectiveness. Throughout the study, participants will attend regular visits for physical performance tests, including the Short Physical Performance Battery SPPB, Timed Up and Go TUG test, handgrip strength measurements, and muscle mass assessments using DXA scans. Quality of life and sarcopenia-related questionnaires will also be completed. Safety and adherence will be closely monitored, with the primary outcome measured at 12 weeks after starting treatment.
CONDITIONS
Brief Title
A Study of AMC6156 in People With Sarcopenia
Research Team
J
Jooyeon Kim
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
